There is robust evidence that A2AR antagonism attenuates behavioral and neurochemical features of Parkinson’s disease (PD) (reviewed, e.g., in [14, 15]), which has heralded the recent approval by the FDA of the first A2AR antagonist to manage PD [16]. The gene discussed is ADORA2A; the disease is Parkinson disease.